15 jun: Fredagens aktier: Cyklisk fremgang inden afgørende græsk valg
18 jun: USA/aktier: Græsk valg sender futures højere
15-06-2012 23:53:00

Merck Loses Nasonex Patent Suit; Says Likely to Appeal

Relateret indhold

By Ben Fox Rubin

Drug maker Merck & Co. (MRK) said a U.S. district court ruled against it in a patent-infringement suit involving Apotex Inc.

In 2009, Merck filed the suit in New Jersey in an effort to block Apotex, a Canadian generic drug manufacturer, from selling a generic copy of Merck's blockbuster allergy drug Nasonex before U.S. patent protection expires.

Apotex had challenged the validity of the U.S. patent covering Nasonex. Merck said its patent for Nasonex is due to expire in 2018.

Bruce N. Kuhlik, Merck's general counsel, said his company was pleased the court ruled that its patent on Nasonex is valid, but was disappointed the court said the patent wasn't infringed by Apotex's product.

"Today's decision reflects just one step in the lengthy patent litigation process, and we plan to review all of our options, including a likely appeal of the decision," Mr. Kuhlik said.

Merck, like its rivals, has been cutting costs as part of an effort to soften the hit from increased generic competition. The company's top-selling allergy and asthma medication Singulair loses patent exclusivity in August and the ripple-effect from generic versions of rival Pfizer Inc.'s (PFE) cholesterol fighter Lipitor have contributed to a decline in sales of Merck's anticholesterol drug Vytorin.

In April, Merck said its first-quarter earnings rose 67% as the drug maker's cost controls helped offset slower-than-expected sales growth.

Shares closed Friday at $38.94 and were down 14 cents after hours. The stock is up 3.3% year-to-date.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 15, 2012 17:53 ET (21:53 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Mærsk: Markant stigning til raterne for Asien-Nordeuropa-ruter

01-07-2016 15:17:11
Raterne for containersejlads på ruterne mellem Asien og Nordeuropa, som er af særlig vigtighed for A.P. Møller Mærsks containerrederi, Maersk Line, fik endnu et..

Egetæpper/CFO: Slår over på kort lys efter brexit

01-07-2016 14:07:57
Efter at have kørt med langt lys og fokuseret på, hvad der skal ske flere år frem, så har ledelsen hos Egetæpper efter sidste uges britiske EU-afstemning slået ..

Aktier/åbning: Genmab tager igen teten i stigende C20

01-07-2016 09:28:23
De danske eliteaktier lægger an til en stigning for fjerde dag i træk. Forrest ligger Genmab, der i den seneste tid ofte har ligget i spidsen, når der er fremga..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Ny stigning vej til C20
2
Vestas vinder ordre på 162 MW i USA
3
Danmark/Danske: Sænker BNP-skøn markant - NY
4
Aktier/middag: Fuld skrue for Mærsk i optimistisk C20
5
Harboe/Danske: Anbefaler nu at købe aktien og hæver kursmål

Relaterede aktiekurser

Merck & Company Inc (new.. 57,94 0,6% Stigning i aktiekurs
Merck AND CO Inc 52,00 0,3% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
1. juli 2016 22:38:31
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160627.1 - EUROWEB4 - 2016-07-01 22:38:31 - 2016-07-01 22:38:31 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x